Chronic Migraine Clinical Trial
Official title:
Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients
Verified date | October 2021 |
Source | Universidad Autonoma de Madrid |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to know wich combination of treatments are the most effective in patients with chronic migraine. The study design is a simple blind randomized controlled trial (outcomes assessor). The study population: Men and women aged from 18 to 70 years old with chronic migraine for at least 12 weeks. Interventions: A combination of techniques during 6 weeks (6 sessions; 1 per week)
Status | Completed |
Enrollment | 86 |
Est. completion date | October 2019 |
Est. primary completion date | October 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - subjects diagnosed with chronic migraine - Neck, shoulder or spine pain for at least 12 weeks - Continuous headache may be chronic daily headache or tension headache - Patients having the willing to undergo the treatment Exclusion Criteria: - Patients undergoing physical another therapy treatment in cervical or head areas. - Patient with degenerative neurological syndrome or fibromyalgia - Patients with severe cognitive impairment - Patients undergo any neck, head or shoulder surgical process |
Country | Name | City | State |
---|---|---|---|
Spain | Unidad de Ciencias Neurológicas | Madrid |
Lead Sponsor | Collaborator |
---|---|
Universidad Autonoma de Madrid |
Spain,
Andrasik F, Buse DC, Grazzi L. Behavioral medicine for migraine and medication overuse headache. Curr Pain Headache Rep. 2009 Jun;13(3):241-8. Review. — View Citation
Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep. 2003 Oct;7(5):371-6. Review. — View Citation
Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology. 2013 Oct 1;81(14):1260-8. doi: 10.1212/WNL.0b013e3182a6cb32. Epub 2013 Aug 28. Review. — View Citation
Buse DC, Andrasik F. Behavioral medicine for migraine. Neurol Clin. 2009 May;27(2):445-65. doi: 10.1016/j.ncl.2009.01.003. Review. — View Citation
Calhoun AH, Ford S, Millen C, Finkel AG, Truong Y, Nie Y. The prevalence of neck pain in migraine. Headache. 2010 Sep;50(8):1273-7. doi: 10.1111/j.1526-4610.2009.01608.x. Epub 2010 Jan 18. — View Citation
Carlson CR. Psychological considerations for chronic orofacial pain. Oral Maxillofac Surg Clin North Am. 2008 May;20(2):185-95, vi. doi: 10.1016/j.coms.2007.12.002. Review. — View Citation
Daviet JC, Bonan I, Caire JM, Colle F, Damamme L, Froger J, Leblond C, Leger A, Muller F, Simon O, Thiebaut M, Yelnik A. Therapeutic patient education for stroke survivors: Non-pharmacological management. A literature review. Ann Phys Rehabil Med. 2012 Dec;55(9-10):641-56. doi: 10.1016/j.rehab.2012.08.011. Epub 2012 Sep 7. Review. English, French. — View Citation
Finocchi C, Villani V, Casucci G. Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence. Neurol Sci. 2010 Jun;31 Suppl 1:S95-8. doi: 10.1007/s10072-010-0297-2. Review. — View Citation
Gerber WD, Schoenen J. Biobehavioral correlates in migraine: the role of hypersensitivity and information-processing dysfunction. Cephalalgia. 1998 Feb;18 Suppl 21:5-11. Review. — View Citation
Grazzi L, Bussone G. What future for treatment of chronic migraine with medication overuse? Neurol Sci. 2011 May;32 Suppl 1:S19-22. doi: 10.1007/s10072-011-0553-0. Review. — View Citation
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658. — View Citation
Kindelan-Calvo P, Gil-Martínez A, Paris-Alemany A, Pardo-Montero J, Muñoz-García D, Angulo-Díaz-Parreño S, La Touche R. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med. 2014 Sep;15(9):1619-36. doi: 10.1111/pme.12505. Epub 2014 Aug 26. Review. — View Citation
Latimer KM. Chronic headache: stop the pain before it starts. J Fam Pract. 2013 Mar;62(3):126-33. Review. — View Citation
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9. — View Citation
Louw A, Diener I, Butler DS, Puentedura EJ. The effect of neuroscience education on pain, disability, anxiety, and stress in chronic musculoskeletal pain. Arch Phys Med Rehabil. 2011 Dec;92(12):2041-56. doi: 10.1016/j.apmr.2011.07.198. Review. — View Citation
Nicholson R, Nash J, Andrasik F. A self-administered behavioral intervention using tailored messages for migraine. Headache. 2005 Oct;45(9):1124-39. — View Citation
Pozo-Rosich P. [Chronic migraine: its epidemiology and impact]. Rev Neurol. 2012 Apr 10;54 Suppl 2:S3-11. Review. Spanish. — View Citation
Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache. 2005 May;45 Suppl 2:S92-109. Review. — View Citation
Ruscheweyh R, Müller M, Blum B, Straube A. Correlation of headache frequency and psychosocial impairment in migraine: a cross-sectional study. Headache. 2014 May;54(5):861-71. doi: 10.1111/head.12195. Epub 2013 Aug 23. — View Citation
Stanos S. Focused review of interdisciplinary pain rehabilitation programs for chronic pain management. Curr Pain Headache Rep. 2012 Apr;16(2):147-52. doi: 10.1007/s11916-012-0252-4. Review. — View Citation
Volcy M, Sheftell FD, Tepper SJ, Rapoport AM, Bigal ME. Tinnitus in migraine: an allodynic symptom secondary to abnormal cortical functioning? Headache. 2005 Sep;45(8):1083-7. — View Citation
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Life measured by the HIT-6 Questionnaire | A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life. | Baseline | |
Secondary | Cervical range of Motion measured by CROM ( cervical range of motion device) | The distance and direction to which a bone joint can be extended. Range of motion is a function of the condition of the joints, muscles, and connective tissues involved. Joint flexibility can be improved through appropriate MUSCLE STRETCHING EXERCISES. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Temporal Summation measured by Von Frey filament | Postsynaptic Potential Summation: Physiological integration of multiple SYNAPTIC POTENTIAL signals to reach the threshold and initiate postsynaptic ACTION POTENTIALS. In spatial summation stimulations from additional synaptic junctions are recruited to generate s response. In temporal summation succeeding stimuli signals are summed up to reach the threshold. The postsynaptic potentials can be either excitatory or inhibitory (EPSP or IPSP).) | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Sleep Disorders measured by Latineen index score | Conditions characterized by disturbances of usual sleep patterns or behaviors. Sleep disorders may be divided into three major categories: DYSSOMNIAS (i.e. disorders characterized by insomnia or hypersomnia), PARASOMNIAS (abnormal sleep behaviors), and sleep disorders secondary to medical or psychiatric disorders | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Medication Adherence scored by a medication calendar | Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Cope (Adaptation, Psychological) measured by CADC questionnaire ( Adaptation of the Chronic Pain self-efficacy Scale) and CAD- R questionnaire | A state of harmony between internal needs and external demands and the processes used in achieving this condition | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Anxiety measured by EUROQOL score | Feeling or emotion of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Catastrophization measured by PCS ( Pain Catastrophizing Scale) | Cognitive and emotional processes encompassing magnification of pain-related stimuli, feelings of helplessness, and a generally pessimistic orientation. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Phobic Disorders measured by Chronic Pain self-efficacy Scale, BECK | Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Disability Evaluation measured by neck disability Index and CF-PDI ( Craniofacial pain and disability inventory) | Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits.
Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits. Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits. |
Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Self Efficacy measured by Chronic Pain self-efficacy Scale | Cognitive mechanism based on expectations or beliefs about one's ability to perform actions necessary to produce a given effect. It is also a theoretical component of behavior change in various therapeutic treatments. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Pain perception outcome assessed by VAS | The process by which PAIN is recognized and interpreted by the brain. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Quality of Life measured by the HIT-6 Questionnaire | A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Physical activity measured by IPAQ ( International physical Activity questionnaire) | The performance of the basic activities of self care or sport such as dressing, ambulation, eating, walking or practicing sports. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Pain Threshold measured by algometer | Amount of stimulation required before the sensation of pain is experienced. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Pain behaviour assessed by PBQ questionnaire ( Pain behaviour questionnaire) | The process by which PAIN is recognized and interpreted by the brain. | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year | |
Secondary | Kinesiophobia measured by TSK ( Tampa Scale of Kinesiophobia) | Fear of having a painfull experience due to mevement | Baseline , 6 weeks, 2 months, 4 months, 6 months, one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Enrolling by invitation |
NCT02291380 -
A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine
|
Phase 3 | |
Withdrawn |
NCT02122744 -
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
|
N/A | |
Completed |
NCT02122237 -
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
|
Phase 3 | |
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01709708 -
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
|
Phase 4 | |
Completed |
NCT01741246 -
Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging
|
N/A | |
Completed |
NCT01090050 -
Treximet in the Treatment of Chronic Migraine
|
Phase 4 | |
Recruiting |
NCT03507400 -
Introvision for Migraine and Headaches
|
N/A | |
Completed |
NCT04161807 -
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
|
N/A | |
Completed |
NCT03175263 -
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain
|
N/A | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT01700387 -
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
|
Phase 4 | |
Completed |
NCT01667250 -
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT01135784 -
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
|
Phase 2 | |
Completed |
NCT00772031 -
NINDS CRC Chronic Migraine Treatment Trial
|
Phase 3 | |
Completed |
NCT01496950 -
Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine
|
Phase 1 |